ArticleCase reports in nephrology and dialysis
Deploying an FcMBL-Based Extracorporeal Blood Purification Filter in a Critically Ill Patient with COVID-19.
Article in Case reports in nephrology and dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of COVID-19, can progress to life-threatening disease and multiorgan failure, and the degree of circulating SARS-CoV-2 directly correlates to clinical deterioration and mortality. The engineered FcMBL protein binds numerous pathogens, including SARS-CoV-2, and pathogenic debris known as pathogen-associated molecular patterns (PAMPs). Case Presentation: We report the first clinical use of an extracorporeal filter utilizing FcMBL to bind and remove pathogens and PAMPs from the circulation of a critically ill patient with COVID-19-induced multiorgan failure. Conclusion: This case highlights the feasibility of using the novel filter to reduce the circulating pathogen load in patients with severe infection through the use of agnostic pathogen binding via FcMBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.